Organogenesis (NASDAQ:ORGO) Earns Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Organogenesis (NASDAQ:ORGO - Free Report) in a research report report published on Tuesday,Benzinga reports. Cantor Fitzgerald currently has a $7.00 price target on the stock.

Organogenesis Trading Up 0.2%

Organogenesis stock traded up $0.01 during trading on Tuesday, reaching $4.37. The company had a trading volume of 347,253 shares, compared to its average volume of 1,142,493. Organogenesis has a 52 week low of $2.28 and a 52 week high of $6.71. The firm's 50-day simple moving average is $3.44 and its 200 day simple moving average is $3.89. The firm has a market capitalization of $554.33 million, a price-to-earnings ratio of -25.71 and a beta of 1.70.

Organogenesis (NASDAQ:ORGO - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of $0.04 by ($0.17). The business had revenue of $86.69 million for the quarter, compared to the consensus estimate of $90.77 million. Organogenesis had a negative net margin of 3.46% and a negative return on equity of 4.00%. On average, analysts predict that Organogenesis will post -0.07 earnings per share for the current year.

Insider Buying and Selling

In other Organogenesis news, insider Lori Freedman purchased 9,022 shares of the firm's stock in a transaction on Friday, June 6th. The shares were acquired at an average cost of $2.99 per share, with a total value of $26,975.78. Following the completion of the acquisition, the insider directly owned 846,459 shares in the company, valued at $2,530,912.41. The trade was a 1.08% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders bought 252,264 shares of company stock worth $725,732 over the last quarter. 33.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On Organogenesis

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Farther Finance Advisors LLC bought a new stake in shares of Organogenesis in the second quarter worth about $35,000. Virtu Financial LLC bought a new stake in shares of Organogenesis in the fourth quarter worth about $38,000. Merit Financial Group LLC bought a new stake in shares of Organogenesis in the first quarter worth about $45,000. ProShare Advisors LLC increased its holdings in shares of Organogenesis by 49.0% in the fourth quarter. ProShare Advisors LLC now owns 20,329 shares of the company's stock worth $65,000 after purchasing an additional 6,689 shares during the last quarter. Finally, Victory Capital Management Inc. bought a new stake in shares of Organogenesis in the first quarter worth about $67,000. 49.57% of the stock is owned by institutional investors.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.